Chemically defined immunotherapeutic agents.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001388:Aziridines / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D004050:Ditiocarb / Q000627:therapeutic use; D006801:Humans; D007042:Hypoxanthines / Q000627:therapeutic use; D007542:Inosine Pranobex / Q000627:therapeutic use; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D011713:Pyran Copolymer / Q000627:therapeutic use; D014405:Tuftsin / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001388:Aziridines; D001562:Benzimidazoles; D007042:Hypoxanthines; D011713:Pyran Copolymer; D007978:Levamisole; C016866:azimexon; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C029171:tilomisole; C026533:NPT 15392; D002927:Cimetidine; C039706:7,8-dihydrothiazole(3,2e)hypoxanthine; D004050:Ditiocarb; D007930:Leucine; C012211:ubenimex; D014405:Tuftsin; D007542:Inosine Pranobex